Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase I Oncology
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
What is being tested: VB10.16 (therapeutic DNA vaccine) combined with pembrolizumab (PD-1 inhibitor) in patients with unresectable recurrent or metastatic HPV16-positive oropharyngeal head and…
26 Aug 2026 NCT06016920
active not recruiting Phase I Oncology
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
Phase 1 trial testing dostarlimab, a new PD-1 immunotherapy antibody, for safety and effectiveness in advanced cancer patients.
25 Aug 2026 NCT02715284
● Recruiting Phase I Dermatology
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
Study comparing how the body processes nusinersen delivered via an implantable device versus lumbar puncture in spinal muscular atrophy patients.
24 Aug 2026 NCT06555419
● Recruiting Phase I Neurology
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer’s Disease
Drug being tested: DNL921 is a novel investigational agent undergoing Phase 1/1b evaluation for safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and…
20 Aug 2026 NCT07758595
● Recruiting Phase I Cardiology / Cardiovascular
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Treatment being tested: Cevostamab (a novel therapeutic agent) administered as monotherapy or in combination with established multiple myeloma regimens (pomalidomide/dexamethasone or daratumumab/dexamethasone) to evaluate…
20 Aug 2026 NCT04910568
● Recruiting Phase I Cardiology / Cardiovascular
A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure
Investigational Agent: NNC0537-1482 is a novel drug being evaluated for safety, tolerability, and pharmacological efficacy in heart failure patients—addressing an unmet therapeutic need in…
18 Aug 2026 NCT07218627
active not recruiting Phase I
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Early-stage trial testing a new antibody drug (cevostamab) alone or combined with existing treatments for hard-to-treat multiple myeloma.
17 Aug 2026 NCT04910568
active not recruiting Phase I / Phase II Oncology
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
ODM-208 showed acceptable safety in advanced prostate cancer patients, supporting further development of this new treatment.
14 Aug 2026 NCT03436485
● Recruiting Phase I / Phase II Neurology
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
Gene therapy AVB-101 delivered to the brain as one-time treatment for early-onset dementia caused by progranulin protein deficiency.
13 Aug 2026 NCT06064890
active not recruiting Phase I Oncology
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Early-stage study testing a new cancer drug (tuvusertib) alone and combined with niraparib in advanced solid tumors to assess safety and effectiveness.
13 Aug 2026 NCT04170153
● Recruiting Phase I Rheumatology
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
What is being tested: AZD0120, a dual CAR T cell therapy targeting CD19 and BCMA, is being investigated as a potential treatment for adults…
12 Aug 2026 NCT06897930
● Recruiting Phase I Oncology
Anti-GD2 ADC M3554 in Advanced Solid Tumors
What is being tested: M3554 is an anti-GD2 antibody-drug conjugate (ADC) being evaluated for dose optimisation and safety assessment in patients with advanced soft…
12 Aug 2026 NCT06641908
● Recruiting Phase I Oncology
TT-702 in Patients With Advanced Solid Tumours.
What is being tested: TT-702 is a novel drug candidate undergoing evaluation for safety, tolerability, and optimal dosing in patients with advanced solid tumours,…
12 Aug 2026 NCT05272709
active not recruiting Phase I Oncology
Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma
CD19 CAR T-cell therapy tested for safety and effectiveness in patients with relapsed/refractory brain lymphoma.
11 Aug 2026 NCT04443829
● Recruiting Phase I / Phase II
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
Gene therapy SRP-1003 tested for safety and effectiveness in patients with type 1 myotonic dystrophy.
11 Aug 2026 NCT06138743
● Recruiting Phase I Oncology
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Investigational Agent: GDC-1261 is being tested for the first time in prostate cancer patients to assess its safety profile, how the body processes it…
11 Aug 2026 NCT07567846
● Recruiting Phase I Respiratory / COPD / Asthma
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
TSRA-196 is being tested as a potential therapeutic intervention in adults with PiZZ alpha-1 antitrypsin deficiency (AATD), a serious genetic disorder causing progressive lung…
11 Aug 2026 NCT07227207
● Recruiting Phase I Oncology
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
What is being tested: A combination of bexmarilimab (a CSF-1R inhibitor) with nivolumab (a PD-1 checkpoint inhibitor) in patients with advanced melanoma and non-small…
11 Aug 2026 NCT07718243
● Recruiting Phase I Oncology
A Study of MGC026 in Participants With Advanced Solid Tumors
What is being tested: MGC026, a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity in patients with advanced…
11 Aug 2026 NCT06242470
● Recruiting Phase I Oncology
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
What is being tested: KCAT19 evaluates allogeneic T cells engineered with dual receptors (TCR-KDEL and CAR-targeting CD19) as a novel immunotherapy for advanced, treatment-resistant…
11 Aug 2026 NCT05391490
● Recruiting Phase I / Phase II Rare Diseases
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Gene therapy trial testing safety and effectiveness of DB-OTO for hearing loss caused by otoferlin gene mutations in children and adults.
05 Aug 2026 NCT05788536
active not recruiting Phase I / Phase II
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Early-stage trial testing epcoritamab (new antibody) for treatment-resistant B-cell lymphoma, measuring safety, dosing, and effectiveness.
04 Aug 2026 NCT03625037
● Recruiting Phase I / Phase II
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
Early-stage trial testing a new drug (ALE1) for safety and effectiveness in healthy people and those with hypophosphatasia.
03 Aug 2026 NCT07179640
active not recruiting Phase I / Phase II Oncology
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
A radioactive drug combined with standard chemotherapy and immunotherapy is being tested in newly diagnosed extensive small cell lung cancer.
03 Aug 2026 NCT05142696
active not recruiting Phase I / Phase II Oncology
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Trial testing combined amivantamab and capmatinib drugs in advanced lung cancer with specific genetic mutations to find safe, effective doses.
31 Jul 2026 NCT05488314
active not recruiting Phase I
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
New drug JNJ-90009530 tested in patients with hard-to-treat B-cell lymphoma to find safe doses and whether it works.
31 Jul 2026 NCT05784441
● Recruiting Phase I Oncology
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Drug Being Tested: ART0380, a novel therapeutic agent being evaluated for safety, tolerability, and efficacy in patients with advanced or metastatic solid tumors, with…
30 Jul 2026 NCT04657068
● Recruiting Phase I Oncology
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
What is being tested: MCLA-158, a bispecific antibody, is being evaluated as a single-agent treatment in patients with advanced solid tumors, with completed dose…
29 Jul 2026 NCT03526835
active not recruiting Phase I / Phase II
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
New drug povetacicept tested in adults with autoimmune blood disorders to assess safety and effectiveness over six months.
28 Jul 2026 NCT05757570
active not recruiting Phase I
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
Early-stage trial testing safety of ARGX-119 infusions in adults with DOK7 muscle weakness syndrome.
24 Jul 2026 NCT06436742
active not recruiting Phase I / Phase II Oncology
First-in-Human Study of ICT01 in Patients With Advanced Cancer
New antibody drug (ICT01) tested alone and with pembrolizumab in advanced cancer patients to find safe doses and effectiveness.
23 Jul 2026 NCT04243499
● Recruiting Phase I Oncology
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
What is being tested: MOMA-313, an oral therapeutic agent, is undergoing Phase 1 evaluation for safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity in patients…
23 Jul 2026 NCT06545942
● Recruiting Phase I Oncology
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
What is being tested: INCA33890, a novel investigational agent, is undergoing a dose-escalation safety and tolerability study in patients with advanced or metastatic solid…
23 Jul 2026 NCT05836324
● Recruiting Phase I / Phase II Oncology
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Trial testing ubamatamab alone or combined with cemiplimab in recurrent ovarian and other MUC16-positive cancers, assessing safety, dosing, and effectiveness.
22 Jul 2026 NCT03564340
● Recruiting Phase I Oncology
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Drug being tested: PF-08052667 is a novel investigational medicine being evaluated as monotherapy or in combination with BCG (standard intravesical immunotherapy) and/or sasanlimab (an…
22 Jul 2026 NCT07206225
● Recruiting Phase I Oncology
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
What is being tested: Different dose combinations of BI 1703880 (an experimental medicine) with ezabenlimab (an existing immunotherapy) to determine tolerability and the maximum…
22 Jul 2026 NCT05471856
● Recruiting Phase I Oncology
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
What is being tested: The safety and efficacy of T cell engaging bi/tri-specific antibodies administered intravenously or subcutaneously, either as monotherapy or in combination…
21 Jul 2026 NCT06892522
● Recruiting Phase I Oncology
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
Drug Being Tested: GSK5533524, a novel investigational agent, is being evaluated in a first-in-human study as monotherapy and in combination regimens to establish safety,…
21 Jul 2026 NCT07438782
● Recruiting Phase I Oncology
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Drug and mechanism: LOXO-783 is being tested as a targeted therapy for breast cancer and solid tumors with specific genetic mutations, representing a precision…
20 Jul 2026 NCT05307705
active not recruiting Phase I
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants
A safety and dose study of new drug UCB5285 in healthy people, including Japanese volunteers.
17 Jul 2026 NCT07286682
● Recruiting Phase I Gastroenterology
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
A new gene-editing treatment (VERVE-201) was tested in patients with severe high cholesterol to assess safety and whether it reduces cholesterol levels.
17 Jul 2026 NCT06451770
● Recruiting Phase I Respiratory / COPD / Asthma
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
What is being tested: A controlled human infection model (CHIM) administering SARS-CoV-2 Omicron EG.5.1 variant via intranasal drops to evaluate breakthrough infections and immune…
17 Jul 2026 NCT07397455
active not recruiting Phase I / Phase II
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Single-dose gene therapy injection for wet age-related macular degeneration, with safety and vision outcomes tracked over five years.
16 Jul 2026 NCT06660667
active not recruiting Phase I
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
Phase 1 trial testing a new drug (GSK4771261) in healthy people and those with polycystic kidney disease to assess safety and effectiveness.
15 Jul 2026 NCT06734234
active not recruiting Phase I / Phase II Oncology
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Early-stage trial testing JNJ-63723283 (anti-PD-1 antibody) to find safe doses and effectiveness across multiple advanced cancers.
14 Jul 2026 NCT02908906
● Recruiting Phase I Oncology
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
What is being tested: mRNA-4359, a novel immunotherapy agent, is being evaluated for safety and tolerability when administered as monotherapy and in combination with…
14 Jul 2026 NCT05533697
● Recruiting Phase I Oncology
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
What is being tested: GSK5764227, a novel therapeutic agent, is being evaluated for safety, efficacy, and pharmacokinetics as monotherapy or in combination with other…
14 Jul 2026 NCT06885034
● Recruiting Phase I / Phase II Rare Diseases
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
LY3884961 (PR001) safety and tolerability study in adults with peripheral Gaucher disease across multiple dose levels over five years.
13 Jul 2026 NCT05487599
● Recruiting Phase I Oncology
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors
What is being tested: LRK-4189, an investigational agent, is being evaluated as a monotherapy and in combination regimens for treating solid tumors, with particular…
13 Jul 2026 NCT07498725
● Recruiting Phase I Oncology
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
LY4152199 is a novel investigational agent being evaluated for dose-optimisation, safety, and efficacy in patients with relapsed or refractory B-cell malignancies who have failed…
10 Jul 2026 NCT07101328